Press Releases

ACE is proud to be referenced as a pioneer of accreditation standards in the new health policy statement from the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography (ACC/AHA/SCAI). The policy statement defines new standards for structured reporting of clinical and operational data in the cardiac catheterization laboratory. With the new policy statement, ACC/AHA/SCAI notes the “increasing importance of accreditation of cardiac catheterization laboratories.”

ZZ Biotech today announced that the National Institutes of Health will support a multicenter Phase 2 clinical trial of its experimental drug, 3K3A-APC, in patients suffering from acute ischemic stroke.

The Endurant AAA stent graft system from Medtronic, Inc. continues to demonstrate exceptional long-term performance in the endovascular treatment of abdominal aortic aneurysms, according to new clinical data presented for the first time at the 2014 Charing Cross international symposium in London.

Celladon Corporation, a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative.

Two researchers from the Perelman School of Medicine at the University of Pennsylvania and the Penn Cardiovascular Institute (CVI) are among the 2014 recipients of the prestigious Clinical Research Achievement Award for their work in cardiovascular science. The awards are presented by the Clinical Research Forum to physician scientists from across the country. Ten projects are selected annually that represent outstanding examples of research projects that benefit the health and wellbeing of the general public. This is the first time that one academic institution has had two recipients honored in one year.

GE Healthcare today announced results from a new study, which showed that patients receiving Visipaque(tm) (iodixanol) 320mg I/ml reported less discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue(r) (iopamidol) 370 mg I/ml during peripheral arteriography. As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, warmth or pain. The data were presented at the American College of Cardiology's 63rd Annual Scientific Session and Expo.

Medtronic today announced CE (Conformité Européenne) Mark and European launch of the Evera MRI(tm) SureScan implantable cardioverter-defibrillator (ICD) System, the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. The Medtronic Evera MRI ICD is not approved in the United States.

The Adult Congenital Heart Association (ACHA), a national nonprofit organization dedicated to improving and extending the lives of adults with congenital heart defects (CHD), announced today the appointment of Glenn R. Tringali as its new National Executive Director.

Patients with peripheral artery disease in the upper leg experienced significantly better outcomes at 12 months after treatment with the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. than with standard balloon angioplasty, according to a landmark clinical study reported on today for the first time.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received CE Mark for the advanced EDWARDS INTUITY Elite valve system. This next-generation, rapid deployment system facilitates smaller incisions in surgical aortic valve replacement (AVR) procedures, and is built upon extensive evidence supporting the durability of the Carpentier-Edwards PERIMOUNT heart valve design.

UltraSPECT, provider of the only multi-vendor and most cost-effective imaging solution for meeting the American Society of Nuclear Cardiology (ASNC) low dose guidelines, announces today that Hamilton Cardiology Associates (HCA), Hamilton Township, New Jersey, will leverage UltraSPECT’s Xpress3.Cardiac software to reduce radiation exposure and shorten exam time for patients. HCA is a full service cardiology practice with 12 physicians including six board certified nuclear cardiologists, and has been serving Mercer County and its surrounding areas for more than 20 years.

College football players tend to have stiffer arteries than other college students, even before their college athletic careers have started, cardiology researchers have found.

The Detroit Medical Center (DMC) is the first in the Midwest to use a new, state-of-the-art system for treating Coronary Artery Disease (CAD).

OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the COMBO Stent for the treatment of coronary lesions in the setting of routine clinical care. The registry enrolled 1,000 patients at nine European high-volume percutaneous coronary intervention centers in France, Latvia, Luxembourg, The Netherlands, United Kingdom and Spain.

Stamford, Conn., March 27, 2014 - FUJIFILM Medical Systems U.S.A., Inc. will highlight an integrated Synapse portfolio that allows cardiologists  and clinical professionals to enhance patient care through optimized productivity at the 63rd Annual Scientific Session & Expo of the American College of Cardiology (ACC) on March 29 - 31 in Washington, DC.

WASHINGTON, DC – March 27, 2014 –A new angiographic analysis of the CHAMPION PHOENIX trial examined the incidence and impact of stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI). Results of the study were released today and will be presented March 30 at the American College of Cardiology 63rd Annual Scientific Session.

RIDGEFIELD, Conn., March 28, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from a new survey of cardiologists to understand their perceptions about anticoagulation, stroke risk reduction and goals for non-valvular atrial fibrillation (NVAF) therapy when prescribing warfarin or a novel oral anticoagulant. The online survey, conducted by Harris Poll on behalf of BIPI, included 300 licensed U.S. cardiologists who treat at least five NVAF patients per month.

WASHINGTON, D.C., March 28, 2014 – With the unmatched flexibility to measure radiation peak skin dose in real time, Toshiba America Medical Systems, Inc.’s Dose Tracking System is the latest advancement in optimizing dose management for its InfinixTM-i cardiovascular X-ray systems during adult and pediatric interventional procedures.

BURLINGTON, Mass. – March 26, 2014 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, today announced that its TVC Imaging System™, a first-in-class dual-modality intravascular imaging system, will be featured in eight scientific posters during the American College of Cardiology’s (ACC) 63rd Annual Scientific Session. The meeting will be held March 29th-31st at the Walter E. Washington Convention Center in Washington, DC.

March 27, 2014—Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, DC. These sub-analyses specifically investigated the effects of the dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin on rates of CV mortality and hospitalization for heart failure (HF).

PRINCETON, N.J., & NEW YORK (March 27, 2014) -- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis (apixaban) compared to warfarin according to blood pressure control.1 The results showed that poor blood pressure control was associated with a substantially higher risk of stroke or systemic embolism, independent of Eliquis or warfarin treatment. However, this subanalysis found consistent results for Eliquis versus warfarin in reducing the risk of stroke, regardless of blood pressure control. These data will be presented Saturday, March 29, at the American College of Cardiology’s (ACC) 63rd Annual Scientific Session in Washington, D.C.